SCHEDULE 13G/A: Farallon Capital Entities Report Zero Beneficial Ownership in Elevation Oncology, Inc.

Farallon Capital and its affiliated entities have filed an amended Schedule 13G, indicating they no longer beneficially own any shares of Elevation Oncology, Inc.'s common stock as of March 31, 2025.

Summary

• This document is an Amendment No. 3 to a Schedule 13G filing concerning beneficial ownership of Elevation Oncology, Inc. (Issuer).
• The filing was made by a group of reporting persons, collectively referred to as 'Farallon Capital Entities', including various Farallon Capital L.P. funds, Farallon Partners, L.L.C., and several individual managing members and managers.
• As of March 31, 2025, the reporting persons collectively hold 0.00 shares of Elevation Oncology, Inc. Common Stock, representing 0% of the class.
• The filing states that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.
• The principal executive offices of Elevation Oncology, Inc. are located at 101 Federal Street, Suite 1900, Boston, Massachusetts, 02110.
• The principal business office of the Reporting Persons is c/o Farallon Capital Management, L.L.C., One Maritime Plaza, Suite 2100, San Francisco, California 94111.

Sentiment

Score: 5

Explanation: The document is a neutral, factual regulatory filing disclosing beneficial ownership. It does not contain information that would inherently convey positive or negative sentiment about the issuer's performance or prospects.

Future Outlook

NA

Industry Context

This filing is a standard regulatory disclosure by an institutional investor group, Farallon Capital, indicating a complete divestment or reduction below the reporting threshold of their stake in Elevation Oncology, Inc. Such filings are common and reflect portfolio adjustments by large investment firms.

Stakeholder Impact

• Shareholders: Indicates that Farallon Capital and its affiliates no longer hold a significant stake in Elevation Oncology, Inc., which could imply a lack of institutional support or a strategic portfolio reallocation by Farallon. However, without context on previous holdings, the impact is limited.
• Investment Professionals: Provides updated information on institutional ownership, which is relevant for tracking major investor positions and potential shifts in market sentiment.

Key Dates

Keywords

SEC filing, Schedule 13G, beneficial ownership, Farallon Capital, Elevation Oncology, common stock, institutional investors, ownership disclosure